# Ainex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ainex

- Industry: Healthcare
- Headquarters: Seoul, South Korea
- Website: www.ainex.io/
- Total disclosed funding: $6.7M
- Latest round: Series C (May 19, 2026)
- Investors on record: 4

## About

Based in South Korea, Ainex Corp. develops advanced AI-driven endoscopy solutions, focusing on enhancing diagnostic accuracy in gastrointestinal procedures through innovative technology.Ainex Corp. specializes in AI-powered medical technology, particularly in the field of endoscopy. Founded in 2019, the company is headquartered in Seoul, South Korea. The founder has a background in building tech-focused ventures, although specific past companies are not disclosed. The company has not announced any pivots in its business strategy or operations. Ainex Corporation specializes in AI-powered endoscopy solutions, particularly its core product, ENAD, which facilitates real-time lesion detection and diagnostic support for both upper and lower gastrointestinal (GI) endoscopy. The ENAD system enhances diagnostic accuracy by assisting clinicians in identifying abnormal lesions during procedures such as gastroscopy and colonoscopy, ultimately aiming to improve patient outcomes. With a significant focus on the Korean healthcare market, ENAD is utilized in over 130 hospitals across the country, demonstrating a clear commitment to advancing medical technology in the field of gastroenterology. The solution is backed by extensive training on a vast database of images, including over 600,000 colorectal polyp images and 80,000 gastric lesion images, ensuring that the AI algorithms are well-equipped to provide precise insights during clinical evaluations.Ainex Corporation generates revenue through its innovative AI endoscopy solutions, primarily by partnering with hospitals and medical facilities that incorporate ENAD into their diagnostic processes. The company's transactions typically involve direct B2B relationships, where hospitals acquire the software as a medical device for clinical use, thus enhancing their endoscopic capabilities. By providing real-time diagnostic support, ENAD serves as an integral tool in hospitals' offerings, leading to improved operational efficiencies and patient care. Specific pricing plans for the software have not been disclosed; however, the company’s strategy emphasizes fostering long-term partnerships with healthcare providers, potentially involving subscription models or licensing agreements for ongoing software support and updates.

## Funding rounds

- Series C, May 19, 2026, $6.7M — Daekyo Investment, SW Investment, Kingo Investment Partners, UON INVESTMENT

## Investors

- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series C
- SW Investment (https://capitalatlas.ai/funds/sw-investment) — Series C
- Kingo Investment Partners (https://capitalatlas.ai/funds/kingo-investment-partners) — Series C
- UON INVESTMENT (https://capitalatlas.ai/funds/uon-investment) — Series C